Cited by 193Rheumatoid Arthritis Research and TherapiesT-cell and B-cell ImmunologyPsoriasis: Treatment and Pathogenesis

Immunometabolism in the development of rheumatoid arthritis

Open access
Weyand, Cornelia M., Goronzy, Jörg J.·2020·Immunological Reviews

Abstract

In rheumatoid arthritis (RA), breakdown of self‐tolerance and onset of clinical disease are separated in time and space, supporting a multi‐hit model in which emergence of autoreactive T cells is a pinnacle pathogenic event. Determining factors in T cell differentiation and survival include antigen recognition, but also the metabolic machinery that provides energy and biosynthetic molecules for cell building. Studies in patients with RA have yielded a disease‐specific metabolic signature, which enables naive CD4 T cells to differentiate into pro‐inflammatory helper T cells that are prone to invade into tissue and elicit inflammation through immunogenic cell death. A typifying property of RA CD4 T cells is the shunting of glucose away from glycolytic breakdown and mitochondrial processing toward the pentose phosphate pathway, favoring anabolic over catabolic reactions. Key defects have been localized to the mitochondria and the lysosome; including instability of mitochondrial DNA due to the lack of the DNA repair nuclease MRE11A and inefficient lysosomal tethering of AMPK due to deficiency of N‐myristoyltransferase 1 (NMT1). The molecular taxonomy of the metabolically reprogrammed RA T cells includes glycolytic enzymes (glucose‐6‐phosphate dehydrogenase, phosphofructokinase), DNA repair molecules (MRE11A, ATM), regulators of protein trafficking (NMT1), and the membrane adapter protein TSK5. As the mechanisms determining abnormal T cell behavior in RA are unraveled, opportunities will emerge to interject autoimmune T cells by targeting their metabolic checkpoints.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/imr.12838

Cites

87 of 87 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The balance between glycolysis and oxidative phosphorylation not only defines ATP yield but might also affect oxidation levels and consumption of metabolites such as glucose and fatty acids.

    “The balance between glycolysis and oxidative phosphorylation in providing energy for the cell not only defines the yield of ATP production but might also affect the levels of oxidation (for example, through the production of mtROS) and the consumption of metabolites (such as glucose and fatty acids)273,274.”

    From The role of mitochondria in rheumatic diseases (2022) · cites this paper as [274]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Weyand, C. M., & Goronzy, J. J.
Affiliations
VA Palo Alto Health Care System (US)
Corresponding author
Weyand, Cornelia M.
Venue
Immunological Reviews
Publisher
Wiley
Published
2020-01-27
Volume
294
Issue
1
Pages
177-187
ISSN
  • 0105-2896 (ISSN-L)
  • 1600-065X
OpenAlex
W3000874222
Cited by
193
References
87
Citations by year
2026: 31 · 2025: 40 · 2024: 30 · 2023: 35 · 2022: 24 · 2021: 16 · 2020: 15
FWCI
3.57
Type
journal article
Language
en
Open access
Locations
  • Immunological Reviews (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
National Institutes of Health (R01AI108891, R01AG045779, U19AI057266, R01AI129191, R01AR042527, R01HL117913, R01AI108906, P01HL129941)
Topics
  • Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
  • Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
Keywords
rheumatoid arthritis, immunometabolism, CD4+ T cells, T cell differentiation, pentose phosphate pathway, mitochondrial DNA repair, MRE11A, NMT1, AMPK, lysosomes, glycolysis, autoreactive T cells, immunogenic cell death, metabolic reprogramming, metabolic checkpoint
MeSH terms
Animals, Arthritis, Rheumatoid, DNA Damage, DNA Repair, Glycolysis, Humans, Macrophages, Mitochondria, CD4-Positive T-Lymphocytes, Autoimmunity, Protein Transport

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review